Quality-of-life considerations with taxane-based therapy in metastatic breast cancer: A case vignette

Clinical Journal of Oncology Nursing

Volumn 17, Issue SUPPL, 2013, Pages 35-40

  Maxwell, Cathy ^a  

^a Advanced Medical Specialties   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; TAXOID;

ARTICLE; BREAST TUMOR; FEMALE; HUMAN; METASTASIS; NURSING; PATHOLOGY; QUALITY OF LIFE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; FEMALE; HUMANS; NEOPLASM METASTASIS; QUALITY OF LIFE; TAXOIDS;

EID: 84873242412     PISSN: 10921095     EISSN: 1538067X     Source Type: Journal    
DOI: 10.1188/13.CJON.S1.35-40     Document Type: Article

References (39)

1. Almadrones, L., & Arcot, R. (1999). Patient guide to peripheral neuropathy. Oncology Nursing Forum, 26, 1359-1360.
2. Almadrones, L., McGuire, D.B., Walczak, J.R., Florio, C.M., & Tian, C. (2004). Psychometric evaluation of two scales assessing functional status and peripheral neuropathy associated with chemotherapy for ovarian cancer: A Gynecologic Oncology Group study. Oncology Nursing Forum, 31, 615-623.
3. American Medical Association. (2007). The physician's role in medication reconciliation-Issues, strategies and safety principles. Retrieved from http://www.ama-assn.org/resources/doc/cqi/med-rec-monograph.pdf
4. Anastasia, P., & Hay, J.W. (2002). Chemotherapy-induced neuropathy: Results of an oncology nurse survey [Abstract 2618]. Proceedings of the American Society of Clinical Oncology. Retrieved from http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=16&abstractID=2618
5. Armstrong, T., Almadrones, L., & Gilbert, M.R. (2005). Chemotherapy-induced peripheral neuropathy. Oncology Nursing Forum, 32, 305-311. doi:10.1188/05.ONF.305-311
6. Authier, N., Gillet, J.P., Fialip, J., Eschalier, A., & Coudore, F. (2000). Description of a short-term Taxol-induced nociceptive neuropathy in rats. Brain Research, 887, 239-249. doi:10.1016/S0006-8993(00)02910-3
7. Bakitas, M.A. (2004). Background noise: The experience of chemotherapy-induced peripheral neuropathy. Nursing Research, 56, 323-331.
8. Barharmand, B.A. (2004). Novel challenges affecting quality of life. In B.A. Barharmand (Ed.), Moving ahead-Challenges with combination therapies for colorectal cancer (pp. 1-5). West Conshohocken, PA: Meniscus Educational Institute.
9. Bodey, G.P. (1986). Infection in cancer patients: A continuing association. American Journal of Medicine, 81(Suppl. 1A), 11-26.
10. Boehmke, M.M., & Dickerson, S.S. (2005). Symptom, symptom experiences, and symptom distress encountered by women with breast cancer undergoing current treatment modalities. Cancer Nursing, 28, 382-389.
11. Bristol-Myers Squibb. (2011). Taxol® (paclitaxel) [Prescribing information]. Retrieved from http://packageinserts.bms.com/pi/pi_taxol.pdf
12. Celgene Corporation. (2012). Abraxane® (nab-paclitaxel) [Prescribing information]. Retrieved from http://www.abraxane.com/hcp/download/Abraxane_Prescribing_Information.pdf
13. Crawford, J., Ozer, H., Stoller, R., Johnson, D., Lyman, G., Tabbara, I.,... Glaspy, J. (1991). Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. New England Journal of Medicine, 325, 164-170.
14. Donovan, D. (2009). Management of peripheral neuropathy caused by microtubule inhibitors. Clinical Journal of Oncology Nursing, 13, 686-694. doi:10.1188/09.CJON.686-694
15. Eli Lilly and Company. (2012). Cymbalta® (duloxetine) [Prescribing information]. Retrieved from http://pi.lilly.com/us/cymbalta-pi.pdf
16. Friese, C.R. (2006). Chemotherapy-induced neutropenia: Important new data to guide nursing assessment and management. Advanced Studies in Nursing, 4, 21-25.
17. Gradishar, W.J., Krasnojon, D., Cheporov, S.V., Makhson, A.N., Manikhas, G.M., Clawson, A., & Iglesias, J. (2012). Phase II trial of nab-paclitaxel compared with docetaxel as first-line chemotherapy in patients with metastatic breast cancer: Final analysis of overall survival. Clinical Breast Cancer, 12, 313-321. doi:10.1016/j.clbc.2012.05.001
18. Gradishar, W.J., Tjulandin, S., Davidson, N., Shaw, H., Desai, N., Bhar, P.,... O'Shaughnessy, J. (2005). Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. Journal of Clinical Oncology, 23, 7794-7803. doi:10.1200/JCO.2005.04.937
19. Green, M.D., Koelbl, H., Baselga, J., Galid, A., Guillem, V., Gascon, P.,... Piccart, M.J. (2003). A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Annals of Oncology, 14, 29-35. doi:10.1093/annonc/mdg019
20. Harris, K.A. (1998). The informational needs of patients with cancer and their families. Cancer Practice, 6, 39-46.
21. Hershman, D.L., Weimer, L.H., Wang, A., Kranwinkel, G., Brafman, L., Fuentes, D.,... Crew, K.D. (2011). Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. Breast Cancer Research and Treatment, 125, 767-774. doi:10.1007/s10549-010-1278-0
22. Kobayashi, N., & Mundel, P. (1998). A role of microtubules during the formation of cell processes in neuronal and non-neuronal cells. Cell Tissue Research, 291, 163-174.
23. Makino, H. (2004). Treatment and care of neurotoxicity from taxane anticancer agents. Breast Cancer, 11, 100-104.
24. Markman, M. (2006). Chemotherapy-induced peripheral neuropathy: Underreported and underappreciated. Current Pain and Headache Reports, 10, 275-278.
25. Oken, M.M., Creech, R.H., Tormey, D.C., Horton, J., Davis, T.E., McFadden, E.T., & Carbone, P.P. (1982). Toxicity and response criteria of the Eastern Cooperative Oncology Group. American Journal of Clinical Oncology, 5, 649-655.
26. Pachman, D.R., Barton, D.L., Watson, J.C., & Loprinzi, C.L. (2011). Chemotherapy-induced peripheral neuropathy: Prevention and treatment. Clinical Pharmacology and Therapeutics, 90, 377-387. doi:10.1038/clpt.2011.115
27. Paice, J.A. (2007). Peripheral neuropathy: Experimental findings, clinical approaches. Journal of Supportive Oncology, 5, 61-63.
28. Pfizer Inc. (2012). Neurontin® (gabapentin) [Prescribing information]. Retrieved from http://www.pfizer.com/products/rx/rx_product_neurontin.jsp
29. Polomano, R.C., & Farrar, J.T. (2006). Pain and neuropathy in cancer survivors. American Journal of Nursing, 106(Suppl. 3), 39-47.
30. Reyes-Gibby, C.C., McCrory, L.L., & Cleeland, C.S. (2003). Variations in patients' self-report of pain by treatment setting. Journal of Pain and Symptom Management, 25, 444-448.
31. sanofi-aventis. (2010). Taxotere® (docetaxel) [Prescribing information]. Retrieved from http://products.sanofi.us/Taxotere/taxotere.html
32. Scripture, C.D., Figg, W.D., & Sparreboom, A. (2006). Peripheral neuropathy induced by paclitaxel: Recent insights and future perspectives. Current Neuropharmacology, 4, 165-172.
33. Smith, E.M., Pang, H., Cirrincione, C., Fleishman, S. B., Paskett, E. D., Fadul, C.E.,... Gilman, P. (2012). CALGB 170601: A phase III double blind trial of duloxetine to treat painful chemotherapy-induced peripheral neuropathy (CIPN) [Abstract CRA9013]. Journal of Clinical Oncology. Retrieved from http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=91721
34. Szpiro, K.A., Harrison, M.B., van den Kerkhof, E.G., & Lougheed, M.D. (2008). Patient education in the emergency department: A systematic review of interventions and outcomes. Advanced Emergency Nursing Journal, 30, 34-39.
35. Tofthagen, C. (2010). Patient perceptions associated with chemotherapy-induced peripheral neuropathy [Online exclusive]. Clinical Journal of Oncology Nursing, 14, E22-E28. doi:10.1188/10.CJON.E22-E28
36. Visovsky, C., Collins, M., Abbott, L., Aschenbrenner, J., & Hart, C. (2007). Putting Evidence Into Practice: Evidence-based interventions for chemotherapy-induced peripheral neuropathy. Clinical Journal of Oncology Nursing, 11, 901-913. doi:10.1188/07.CJON.901-913
37. Wickham, R. (2007). Chemotherapy-induced peripheral neuropathy: A review and implications for oncology nursing practice. Clinical Journal of Oncology Nursing, 11, 361-376. doi:10.1188/07.CJON.361-376
38. Windebank, A.J., Blexrud, M.D., & de Groen, P.C. (1994). Potential neurotoxicity of the solvent vehicle for cyclosporine. Journal of Pharmacology and Experimental Therapeutics, 268, 1051-1056.
39. Wolf, S., Barton, D., Kottschade, L., Grothey, A., & Loprinzi, C. (2008). Chemotherapy-induced peripheral neuropathy: Prevention and treatment strategies. European Journal of Cancer, 44, 1507-1515. doi:10.1016/j.ejca.2008.04.018